Association between anti-apolipoprotein A-1 antibodies and cardiovascular disease in the general population

Panagiotis Antiochos; Pedro Marques-Vidal; Julien Virzi; Sabrina Pagano; Nathalie Satta; François Bastardot; Oliver Hartley; Fabrizio Montecucco; François Mach; Gerard Waeber; Peter Vollenweider; Nicolas Vuilleumier

doi:10.1160/TH16-03-0248

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2016; 116(04): 764-771
DOI: 10.1160/TH16-03-0248

Atherosclerosis and Ischaemic Disease

Schattauer GmbH

Association between anti-apolipoprotein A-1 antibodies and cardiovascular disease in the general population

Results from the CoLaus study

Panagiotis Antiochos

¹Department of Internal Medicine, University Hospital of Lausanne, Lausanne, Switzerland

,

Pedro Marques-Vidal

¹Department of Internal Medicine, University Hospital of Lausanne, Lausanne, Switzerland

,

Julien Virzi

²Division of Laboratory Medicine, Department of Genetics and Laboratory Medicine, Geneva University Hospitals, Geneva, Switzerland

³Department of Human Protein Sciences, Faculty of Medicine, University of Geneva, Geneva, Switzerland

,

Sabrina Pagano

²Division of Laboratory Medicine, Department of Genetics and Laboratory Medicine, Geneva University Hospitals, Geneva, Switzerland

³Department of Human Protein Sciences, Faculty of Medicine, University of Geneva, Geneva, Switzerland

,

Nathalie Satta

²Division of Laboratory Medicine, Department of Genetics and Laboratory Medicine, Geneva University Hospitals, Geneva, Switzerland

³Department of Human Protein Sciences, Faculty of Medicine, University of Geneva, Geneva, Switzerland

,

François Bastardot

¹Department of Internal Medicine, University Hospital of Lausanne, Lausanne, Switzerland

,

Oliver Hartley

⁴Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland

,

Fabrizio Montecucco

²Division of Laboratory Medicine, Department of Genetics and Laboratory Medicine, Geneva University Hospitals, Geneva, Switzerland

⁵Division of Cardiology, Foundation for Medical Researches, Department of Medical Specialties, University of Geneva, Geneva, Switzerland

,

François Mach

⁵Division of Cardiology, Foundation for Medical Researches, Department of Medical Specialties, University of Geneva, Geneva, Switzerland

,

Gerard Waeber

¹Department of Internal Medicine, University Hospital of Lausanne, Lausanne, Switzerland

,

Peter Vollenweider

¹Department of Internal Medicine, University Hospital of Lausanne, Lausanne, Switzerland

,

Nicolas Vuilleumier

²Division of Laboratory Medicine, Department of Genetics and Laboratory Medicine, Geneva University Hospitals, Geneva, Switzerland

³Department of Human Protein Sciences, Faculty of Medicine, University of Geneva, Geneva, Switzerland

› Author Affiliations

Abstract

Summary

We aimed to determine the association between autoantibodies against apolipoprotein A-1 (anti-apoA-1 IgG) and prevalent cardiovascular (CV) disease (CVD) as well as markers of CV risk in the general population. Cross-sectional data were obtained from 6649 subjects (age 52.6 ± 10.7 years, 47.4 % male) of the population-based CoLaus study. CVD was defined as myocardial infarction, angina pectoris, percutaneous revascularisation or bypass grafting for ischaemic heart disease stroke or transient ischaemic attack, and was assessed according to standardised medical records. Anti-apoA-1 IgG and biological markers were measured by ELISA and conventional automated techniques, respectively. Prevalence of high anti-apoA-1 IgG levels in the general population was 19.9 %. Presence of anti-apoA-1 IgG was significantly associated with CVD [odds ratio 1.34, 95 % confidence interval (1.05–1.70), p=0.018], independently of established CV risk factors (CVRFs) including age, sex, hypertension, smoking, diabetes, low and high-density lipoprotein cholesterol levels. The n=455 (6.8 %) study participants with a history of CVD (secondary prevention subgroup) presented higher median anti-ApoA-1 IgG values compared with subjects without CVD (p=0.029). Among patients in the secondary prevention subgroup, those with positive anti-apoA-1 IgG levels had lower HDL (p=0.002) and magnesium (p=0.001) levels, but increased uric acid and high-sensitivity C-reactive protein levels (p=0.022, and p<0.001, respectively) compared to patients with negative anti-apoA-1 IgG levels. In conclusion, anti-apoA-1 IgG levels are independently associated with CVD in the general population and also related to CV biomarkers in secondary prevention. These findings indicate that anti-apoA-1 IgG may represent a novel CVRF and need further study in prospective cohorts.

Keywords

Anti-apolipoprotein A-1 antibodies - cardiovascular disease - high-density lipoprotein cholesterol - biomarker - population-based

Full Text

References

References
1 Libby P, Tabas I, Fredman G. et al. Inflammation and its resolution as determinants of acute coronary syndromes. Circ Res 2014; 114: 1867-1879.
2 Hansson GK.. Immune Mechanisms in Atherosclerosis. Arterioscl Thromb Vasc Biol 2001; 21: 1876-1890.
3 Roux-Lombard P, Pagano S, Montecucco F. et al Auto-antibodies as emergent prognostic markers and possible mediators of ischaemic cardiovascular diseases. Clin Rev Allergy Immunol 2013; 44: 84-97.
4 Zhu J, Quyyumi AA, Rott D. et al. Antibodies to human heat-shock protein 60 are associated with the presence and severity of coronary artery disease: evidence for an autoimmune component of atherogenesis. Circulation 2001; 103: 1071-1075.
5 Mustafa A, Nityanand S, Berglund L. et al. Circulating immune complexes in 50-year-old men as a strong and independent risk factor for myocardial infarction. Circulation 2000; 102: 2576-2581.
6 Nussinovitch U, Shoenfeld Y.. Intravenous immunoglobulin – indications and mechanisms in cardiovascular diseases. Autoimmun Rev 2008; 07: 445-452.
7 Pagano S, Satta N, Werling D. et al. Anti-apolipoprotein A-1 IgG in patients with myocardial infarction promotes inflammation through TLR2/CD14 complex. J Intern Med 2012; 272: 344-357.
8 Montecucco F, Braunersreuther V, Burger F. et al. Anti-apoA-1 auto-antibodies increase mouse atherosclerotic plaque vulnerability, myocardial necrosis and mortality triggering TLR2 and TLR4. Thromb Haemost 2015; 114: 410-422.
9 Delgado Alves J, Ames PR, Donohue S. et al Antibodies to high-density lipoprotein and beta2-glycoprotein I are inversely correlated with paraoxonase activity in systemic lupus erythematosus and primary antiphospholipid syndrome. Arthritis Rheuma 2002; 46: 2686-2694.
10 Batuca JR, Ames PR, Isenberg DA. et al. Antibodies toward high-density lipoprotein components inhibit paraoxonase activity in patients with systemic lupus erythematosus. Ann NY Acad Sci 2007; 1108: 137-146.
11 Batuca JR, Ames PR, Amaral M. et al. Anti-atherogenic and anti-inflammatory properties of high-density lipoprotein are affected by specific antibodies in systemic lupus erythematosus. Rheumatology 2009; 48: 26-31.
12 Srivastava R, Yu S, Parks BW. et al. Autoimmune-mediated reduction of high-density lipoprotein-cholesterol and paraoxonase 1 activity in systemic lupus erythematosus-prone gld mice. Arthritis Rheuma 2011; 63: 201-211.
13 Vuilleumier N, Bas S, Pagano S. et al. Anti-apolipoprotein A-1 IgG predicts major cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheuma 2010; 62: 2640-2650.
14 Vuilleumier N, Bratt J, Alizadeh R. et al. Anti-apoA-1 IgG and oxidized LDL are raised in rheumatoid arthritis (RA): potential associations with cardiovascular disease and RA disease activity. Scand J Rheumatol 2010; 39: 447-453.
15 Pruijm M, Schmidtko J, Aho A. et al. High prevalence of anti-apolipoprotein/A-1 autoantibodies in maintenance hemodialysis and association with dialysis vintage. Therap Apheresis Dialysis 2012; 16: 588-594.
16 Quercioli A, Montecucco F, Galan K. et al. Anti-apolipoprotein A-1 IgG levels predict coronary artery calcification in obese but otherwise healthy individuals. Mediators Inflamm 2012; 2012: 243158.
17 Wick PA, Mombelli A, Pagano S. et al. Anti-apolipoprotein A-1 autoantibodies as biomarker for atherosclerosis burden in patients with periodontitis. J Periodontal Res 2013; 48: 350-356.
18 Vuilleumier N, Reber G, James R. et al. Presence of autoantibodies to apolipoprotein A-1 in patients with acute coronary syndrome further links autoimmunity to cardiovascular disease. J Autoimmunity 2004; 23: 353-360.
19 Keller PF, Pagano S, Roux-Lombard P. et al. Autoantibodies against apolipopro-tein A-1 and phosphorylcholine for diagnosis of non-ST-segment elevation myocardial infarction. J Intern Med 2012; 271: 451-462.
20 Montecucco F, Vuilleumier N, Pagano S. et al. Anti-Apolipoprotein A-1 auto-antibodies are active mediators of atherosclerotic plaque vulnerability. Eur Heart J 2011; 32: 412-421.
21 Vuilleumier N, Charbonney E, Fontao L. et al. Anti-(apolipoprotein A-1) IgGs are associated with high levels of oxidized low-density lipoprotein in acute coronary syndrome. Clin Sci 2008; 115: 25-33.
22 Vuilleumier N, Montecucco F, Spinella G. et al. Serum levels of anti-apolipopro-tein A-1 auto-antibodies and myeloperoxidase as predictors of major adverse cardiovascular events after carotid endarterectomy. Thromb Haemost 2013; 109: 706-715.
23 Vuilleumier N, Rossier MF, Pagano S. et al. Anti-apolipoprotein A-1 IgG as an independent cardiovascular prognostic marker affecting basal heart rate in myocardial infarction. Eur Heart J 2010; 31: 815-823.
24 Mannic T, Satta N, Pagano S. et al. CD14 as a mediator of the Mineralocorticoid Receptor – dependent anti-apolipoproteinA-1 IgG chronotropic effect on cardiomyocytes. Endocrinology 2015; en20151605.
25 Rossier MF, Pagano S, Python M. et al. Antiapolipoprotein A-1 IgG chronotropic effects require nongenomic action of aldosterone on L-type calcium channels. Endocrinology 2012; 153: 1269-1278.
26 Wang M, Tashiro M, Berlin JR.. Regulation of L-type calcium current by intracellular magnesium in rat cardiac myocytes. J Physiol 2004; 555: 383-396.
27 Firmann M, Mayor V, Vidal PM. et al. The CoLaus study: a population-based study to investigate the epidemiology and genetic determinants of cardiovascular risk factors and metabolic syndrome. BMC Cardiovasc Dis 2008; 08: 6.
28 Grundy SM, Cleeman JI, Daniels SR. et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-2752.
29 Elisaf M, Panteli K, Theodorou J. et al. Fractional excretion of magnesium in normal subjects and in patients with hypomagnesemia. Magnesium Res 1997; 10: 315-320.
30 Rothman KJ.. No adjustments are needed for multiple comparisons. Epidemiology 1990; 01: 43-46.
31 Perneger TV.. What's wrong with Bonferroni adjustments. Br Med J 1998; 316: 1236-1238.
32 Bender R, Lange S.. Adjusting for multiple testing--when and how?. J Clin Epidemiol 2001; 54: 343-349.
33 Mendez AJ, Goldberg RB, Arnold PI. et al. Acquired HDL Deficiency Associated With Apolipoprotein A-I Reactive Monoclonal Immunoglobulins. Arterioscl Thromb Vasc Biol 2002; 22: 1740-1741.
34 Heinrich PC, Castell JV, Andus T.. Interleukin-6 and the acute phase response. Biochem J 1990; 265: 621-636.
35 Bataille R, Klein B.. C-reactive protein levels as a direct indicator of interleukin-6 levels in humans in vivo. Arthritis Rheuma 1992; 35: 982-984.
36 Del Gobbo LC, Imamura F, Wu JH. et al Circulating and dietary magnesium and risk of cardiovascular disease: a systematic review and meta-analysis of prospective studies. Am J Clin Nutr 2013; 98: 160-173.
37 Golding J, Northstone K, Miller LL. et al. Differences between blood donors and a population sample: implications for case-control studies. Int J Epidemiol 2013; 42: 1145-1156.
38 Croca S, Bassett P, Chambers S. et al. IgG anti-apolipoprotein A-1 antibodies in patients with systemic lupus erythematosus are associated with disease activity and corticosteroid therapy: an observational study. Arthritis Res Therapy 2015; 17: 26.
39 Vuilleumier N, Lahlou K, Poncet A. et al. Head-to-Head Comparison of Auto-Antibodies for Cardiovascular Outcome Prediction after Myocardial Infarction: a Prospective Study. J Clinic Experiment Cardiol 2011; 02: 1-5.
40 Sorenson RC, Bisgaier CL, Aviram M. et al. Human serum Paraoxonase/Arylesterase's retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids: apolipoprotein A-I stabilizes activity. Arterioscl Thromb Vasc Biol 1999; 19: 2214-2225.
41 Teixeira PC, Ducret A, Ferber P. et al. Definition of human apolipoprotein A-I epitopes recognized by autoantibodies present in patients with cardiovascular diseases. J Biol Chem 2014; 289: 28249-28259.
42 Pagano S, Gaertner H, Cerini F. et al. The Human Autoantibody Response to Apolipoprotein A-I Is Focused on the C- Terminal Helix: A New Rationale for Diagnosis and Treatment of Cardiovascular Disease?. PloS one 2015; 10: e0132780.

Supplementary Material

Online Supplementary Material (PDF)